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ABSTRACT 
Aims: Long-term selenium supplementation may have adverse effects on glucose metabolism 
and risk of type-2 diabetes in selenium-replete populations, such as the US. There is limited trial 
evidence on the effect of selenium supplementation on glucose metabolism in European 
populations whose selenium status is much lower than that of the US. We investigated the effect 
of selenium supplementation at different dose levels on changes in HbA1c after 6 months and 2 
years in a population of relatively low selenium status. 
Materials and methods: The Denmark PRECISE study was a single-centre, randomized, 
double-blinded, placebo-controlled, multi-arm, parallel clinical trial with four groups. In total, 
491 volunteers aged 60-74 years were randomly assigned to treatment with 100, 200, or 300 µg 
selenium/d as selenium-enriched-yeast or placebo-yeast. HbA1c measurements were available for 
489 participants at baseline, 435 at 6 months, and 369 after 2 years of selenium supplementation. 
Analyses were performed by intention to treat.  
Results: The mean (SD) age, plasma-selenium concentration, and blood HbA1c at baseline were 
66.1 (4.1) years, 86.5 (16.3) ng/g, and 36.6 (7.0) mmol/mol, respectively.  During the initial 6-
month intervention period, mean HbA1c (95% CIs) decreased by 1.5 (-2.8 to -0.2) mmol/mol for 
100 µg/d of selenium supplementation and by 0.7 (-2.0 to 0.6) mmol/mol for the 200 and 300 
µg/d groups compared with placebo (P = 0.16 for homogeneity of changes across the four 
groups). After 2 years of selenium supplementation, HbA1c had decreased significantly in all 
treatment groups, with no difference between active treatment and placebo. 
Conclusions: Selenium supplementation in an elderly European population of relatively low 
selenium status did not significantly affect HbA1c levels after 2 years. Our findings corroborate 
a possible U-shaped response of selenium supplementation on glucose metabolism.  
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INTRODUCTION 
Selenium (Se) is a key component of a number of selenoproteins involved in essential functions 
such as redox homeostasis, endocrine and metabolic activities (1).  Because of the potential of 
selenoproteins to protect against oxidative stress, Se was hypothesized to prevent the 
development of several chronic diseases including cancer, cardiovascular disease (CVD), and 
type 2 diabetes.  However, findings from observational studies and randomized clinical trials 
have raised concerns that high Se exposure may lead to adverse cardio-metabolic effects, 
including an increased risk of type 2 diabetes in Se-replete populations such as the US (2-4).  
Indeed, in a post-hoc analysis of the Nutritional Prevention of Cancer (NPC) trial in the 
eastern US, we found Se supplementation (200 µg/day), compared to placebo, increased the risk 
of type 2 diabetes,
 
particularly among individuals with high baseline plasma Se (5).  In addition, 
a number of selenoproteins, primarily selenoprotein P (SEPP1) and glutathione peroxidase 
(GPx1) have been linked with diabetogenic effects (6-9).  
There are gaps in the current available evidence. First, many of the observational studies are 
cross-sectional surveys or prospective investigations based on a single analysis of Se status at 
one time point only, and are therefore subject to reverse causation and incidence/prevalence 
biases (10-13).  Moreover, there have been disappointing findings from several costly clinical 
trials of antioxidant supplements showing not only an absence of health benefits but also 
potential harm (5, 14-18).  Lastly, most previous research in this area has been conducted in 
North American populations where baseline Se status is substantially higher than in Europe.
  
Dietary intakes of Se vary considerably between countries and regions largely due to the 
variability of the Se content of plant foods (and hence of animal forage) from one part of the 
world to another (1, 19).   
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We determined the effect of different doses of Se supplementation (100, 200, and 300 µg/d 
or placebo) on HbA1c levels after 6 months and 2 years in a double-blind, randomized, controlled 
trial in Denmark, a country with lower Se status than that of the US (18, 20).  Double-blind, 
placebo controlled randomized clinical trials are less prone to many types of biases than 
observational studies, and provide the strongest level of evidence on the effect of dietary 
interventions on health outcomes.  
 
MATERIALS AND METHODS  
Study design and sample size 
The Denmark PRECISE (PREvention of Cancer by Intervention with SElenium) pilot study 
(ClinicalTrials.gov ID: NCT01819649) was a single-center, randomized, double-blinded, 
placebo-controlled, multi-arm, parallel clinical trial with four groups (allocation ratio 1:1:1:1) 
run from Odense University Hospital, Denmark (18, 21-22). Denmark PRECISE was one of two 
pilot studies for the proposed international PRECISE trial of Se in cancer prevention; the other 
was carried out in the UK (23-24). No formal power calculations were performed a priori; the 
sample size was set at 500 participants, which was considered sufficient to assess whether 
recruitment, adherence, and retention during follow-up would be sufficient for a large trial. From 
November 1998 to June 1999, 2897 potential participants, males and females aged 60–74 years 
from the County of Funen, Denmark, were invited to take part in the trial; 630 accepted the 
invitation to be screened for inclusion at Odense University Hospital. Exclusion criteria were: A 
Southwest Oncology Group performance-status score > 1, indicating impairment in general well-
being and activities of daily life; active liver or kidney disease; previous diagnosis of cancer 
(excluding non-melanoma skin cancer); diagnosed HIV infection; receiving immunosuppressive 
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therapy; being unable to understand written/spoken information; and receiving ≥ 50 µg/d of Se 
supplements in the previous 6 months. 
Randomization was computer-generated, blocked and non-stratified (18, 21-22). 
Participating couples living at the same address were allocated to the same intervention. 
Participants, research staff and investigators were blinded to treatment assignment (18, 21-22). 
Participants deemed suitable for inclusion provided blood samples and were given yeast tablets 
for an open-label 4-week placebo run-in phase. Those (n=491) who met the inclusion criteria, 
displayed good adherence in the placebo run-in phase, and gave written, informed consent, were 
randomised to 0 (placebo-yeast), 100, 200, or 300 µg/d of Se as Se-enriched yeast 
(SelenoPrecise
©
 Pharma Nord, Vejle, Denmark) (Figure 1). Participant evaluation was carried 
out at Odense University Hospital at baseline, 6, 12, 18 months, 2, 3 and 5 years, as previously 
described in detail (18, 21-22). The intervention was delivered for 5 years and participants were 
followed up, post-treatment, for an additional 10 years for mortality ascertainment. 
The regional Data Protection Agency and Scientific Ethics Committees of Vejle and 
Funen counties approved the study prior to data collection (Journal nr. 19980186). 
 
Baseline measurements 
Demographic characteristics, smoking status, height, weight, and supplement use were collected 
at baseline. Medications used were obtained from medical records. Morbidity data were obtained 
from the Danish National Patient Registry which has records of major and secondary diagnoses 
for all in-patient discharges since 1977 and all emergency and outpatient contacts since 1995 
(25). The Charlson comorbidity index was computed by adding 19 comorbid conditions 
diagnosed prior to randomization (26).  
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Selenium measurement 
As previously described in detail (18, 21-22), total Se was measured gravimetrically (ng/g) in 
lithium-heparin plasma at LGC Limited, Teddington, United Kingdom, by inductively coupled-
plasma mass spectrometry at baseline, 6-months and 5-years. Analysis of a matrix-certified 
reference material indicated good accuracy of the method. The intra-assay coefficients of 
variation (CVs) ranged from 0.5% for samples of high-Se concentration to 3% for samples of 
low-Se concentration. The inter-assay CV was 3.4%. 
 
HbA1c measurement 
HbA1c at baseline and at the 6-month and 2-year visits were measured in stored red blood cells at 
the Department of Clinical Biochemistry, King’s College Hospital, United Kingdom, between 
June and August 2015. Measurements were performed using a Premier Hb9210 System (A 
Menarini Diagnostics Ltd, Winnersh-Wokingham, Berkshire, United Kingdom), employing the 
principles of boronate affinity and high-performance liquid chromatography. Samples were 
diluted 1:300 using the Hamilton Diluter. The intra-assay CVs ranged from 0.9% for samples of 
high HbA1c concentration to 1.2% for samples of low HbA1c concentration. The inter-assay CV 
was 2.8%. HbA1c concentrations were reported in mmol/mol.  
 
Power calculations for intention-to-treat analysis 
The two study endpoints were the differences in HbA1c concentration in each intervention group 
compared with placebo at 6 months and 2 years of follow-up. For the average sample size of 117 
participants retained in each treatment group after 6 months of follow-up and a two-sided 
significance level of 0.05, the power to detect underlying differences of 1, 1.5, and 2 mmol/mol 
in mean HbA1c changes after 6 months of follow-up comparing any active treatment group with 
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placebo were 35.6, 66.4, and 88.9%, respectively. Given the smaller average number of 105 
participants remaining in each group after 2 years of follow-up, the power to detect the same 
differences in mean HbA1c changes after 2 years was 20.4, 39.5, and 61.8%, respectively. 
 
Statistical analysis 
For the analysis of randomized groups, all trial participants were assigned to their randomized 
treatment group, irrespective of compliance (intention-to-treat analysis). The effect of 100, 200, 
and 300 µg/d of Se supplementation on changes in HbA1c after 6 months and 2 years was 
estimated by using a linear mixed model (22-23, 27), with fixed effects for treatment groups, 
follow-up times, and treatment-by-time interactions, and random between-subject variations in 
baseline HbA1c levels (intercepts) and HbA1c changes over follow-up (time slopes). The model is 
specified in detail in the Statistical Appendix. Treatment effects were estimated as the 
differences in mean HbA1c changes from baseline to 6 months and 2 years comparing the three 
active treatment groups with placebo. In sensitivity analyses, we excluded visits after participants 
received diabetes medications at baseline or during the intervention period. 
We also evaluated treatment-effect modifications across pre-specified subgroups defined 
by baseline age (< or ≥ 65 years), sex, smoking status (non-current or current), alcohol drinking 
(≤ or > 2 drinks/week), body mass index (< or ≥ 25 kg/m
2
), baseline plasma Se (< or ≥ 80 ng/g), 
and baseline HbA1c (< or ≥ 42 mmol/mol) by including all main terms and interactions between 
treatment groups, time, and the corresponding covariate as fixed effects in the above mixed 
model.  
In addition to the intention-to-treat analysis, we evaluated the cross-sectional association of 
plasma Se and HbA1c levels at baseline and the longitudinal association between changes in 
plasma Se and HbA1c levels after 6 months (plasma Se measurements were not available at 2 
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years). As described in the Statistical Appendix, we used a linear mixed model (22-23, 28) with 
random intercepts, random time slopes, and fixed slopes for baseline Se levels and Se changes at 
6 months to estimate the mean difference in baseline HbA1c levels per 50-ng/g increase in 
baseline Se levels (cross-sectional association), as well as the difference in mean HbA1c changes 
from baseline to 6 months for each 50-ng/g change in Se levels (longitudinal association). We 
also categorized baseline Se levels and Se changes into quartiles in the above mixed model and 
compared mean baseline HbA1c levels across quartiles of baseline Se and mean HbA1c changes 
after 6 months across quartiles of Se change. Cross-sectional and longitudinal associations were 
adjusted for baseline age (continuous), sex, smoking status (never, former, or current), alcohol 
drinking (≤ 2, 3–10, or > 10 drinks/week), body mass index (continuous), and use of diabetes 
medications.  
All reported P values were two-sided and the significance level was set at 0.05. Statistical 
analyses were performed with Stata, version 14 (StataCorp). 
 
RESULTS 
Participants 
Of the 491 randomized participants, 23 withdrew from treatment before 6 months of follow-up, 
48 dropped out between 6 months and 2 years, and the remaining 420 participants completed the 
2-year follow-up period (Figure 1). The 71 drop-outs before the end of the study period were 
equally distributed across treatment groups (P = 0.36). HbA1c measurements were available for 
489 participants at baseline, 435 at 6 months, and 369 at 2 years (Figure 1). Participants with 
and without available HbA1c measurements at 6 months and 2 years did not differ in baseline 
HbA1c levels or other baseline characteristics (data not shown). Non-protocol use of over-the-
counter Se was deemed to be rare since only one of the 108 participants allocated to placebo 
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(0.9%) had plasma Se concentrations more than two standard deviations above the mean at 6 
months. Six participants were receiving diabetes medications at baseline, six at 6 months, and 14 
at 2 years, with no significant differences between treatment groups at any time (P = 0.70, 0.73, 
and 0.12; respectively). 
 
Analysis of randomized groups 
The mean (SD) age, plasma Se concentration, and HbA1c at baseline were 66.1 (4.1) years, 86.5 
(16.3) ng/g, and 36.6 (7.0) mmol/mol, respectively. There were no significant differences 
between treatment groups at baseline in plasma Se concentrations, HbA1c, or other participant 
characteristics (Table 1). Mean plasma Se concentrations (95% confidence intervals [CIs]) 
increased significantly by 64.8 (57.7 to 71.9) ng/g, 120.9 (113.7 to 128.0) ng/g, and 169.8 (162.4 
to 177.1) ng/g after 6 months of Se supplementation at 100, 200, and 300 µg/d, respectively, but 
were virtually unchanged in the placebo group (P < 0.001 for homogeneity of changes across the 
four groups).  
However, small changes in HbA1c were observed in the treatment groups after 6 months 
of intervention (Table 2). Compared with placebo, mean HbA1c differences (95% CIs) at 6 
months were -1.5 (-2.8 to -0.2) mmol/mol for 100 µg/d and -0.7 (-2.0 to 0.6) mmol/mol for 200 
and 300 µg/d of Se supplementation (P = 0.16 for homogeneity of changes across the four 
groups). The decrease in HbA1c levels between the 100 µg/d Se and placebo groups remained 
significant after excluding participants who received diabetes medications during the initial 6-
month intervention period (change -1.6 mmol/mol, 95% CI -2.9 to -0.3 mmol/mol). In subgroup 
analyses, there were no significant treatment-effect modifications at 6 months by participant 
characteristics (Figure 2), although 300 µg/d of Se supplementation showed larger HbA1c 
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decreases in participants with lower plasma Se concentrations and pre-diabetes HbA1c levels at 
baseline. 
After 2 years, HbA1c decreased significantly in the four treatment groups but there were no 
significant differences between active treatment groups and placebo (Table 2). Compared with 
placebo, mean HbA1c levels (95% CIs) changed by -0.9 (-2.7 to 0.9), 0.1 (-1.7 to 2.0), and -1.0 (-
2.8 to 0.8) mmol/mol for 100, 200, and 300 µg/d of Se supplementation, respectively (P = 0.52 
for homogeneity of changes across the four groups). The exclusion of visits after participants 
received diabetes medications did not materially alter the results at 2 years (data not shown). 
The decrease in HbA1c levels after two years of intervention in the placebo group was not 
explained by selective drop-outs (mean baseline HbA1c levels of 35.7 and 36.1 mmol/mol among 
109 retained participants and 17 drop-outs from the placebo group, respectively, P = 0.77) or 
diabetes treatment initiation (mean HbA1c decrease of 2.0 mmol/mol, 95% CI 0.8 to 3.2 
mmol/mol, after excluding 2 participants in the placebo group who received diabetes 
medications during follow-up). Hawthorne or placebo effects might account for part of the 
observed decline in HbA1c levels over time in this elderly population. Anyway, the estimated 
treatment effects were corrected for changes in the placebo group since they were subtracted 
from the corresponding longitudinal HbA1c changes in the three active treatment groups. 
 
Association between plasma selenium and HbA1c levels 
In cross-sectional analyses at baseline, plasma Se concentrations were not associated with HbA1c 
levels (Table 3). In longitudinal analyses, there was a U-shaped association between changes in 
plasma Se and HbA1c levels after 6 months (Figure 3). Compared with the first quartile of Se 
change, mean (95% CI) HbA1c levels changed by -1.5 (-2.6 to -0.3), -0.4 (-1.5 to 0.8) and 0.3 (-
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0.8 to 1.5) mmol/mol from baseline to 6 months in the second, third, and fourth quartiles, 
respectively (Table 4). 
 
Adverse events 
Eight participants died during the 2-year follow-up period and 21 participants discontinued the 
study due to non-fatal adverse events (Figure 1), with no significant differences between 
treatment groups (P = 0.75 and 0.25; respectively). Eighteen participants withdrew due to 
adverse reactions to treatment (Figure 1), which were mainly hair loss, skin reactions, and 
grooved nails. These reactions were equally distributed across placebo and the three active 
treatment groups (P = 0.63). 
 
DISCUSSION 
Overall, findings from the Denmark PRECISE trial do not support a beneficial or harmful effect 
of Se supplements on glucose metabolism. Specifically, in this European population of elderly 
individuals of relatively low Se status, supplementation at different dose levels of Se did not 
significantly affect HbA1c levels after 2 years of supplementation. However, compared to 
placebo, small beneficial changes in HbA1c were observed in the treatment groups after 6 months 
of intervention, particularly at the lowest dose level of Se supplementation (100 µg/d).  
The latter finding seems to corroborate the notion of a U-shaped association of selenium status 
and supplementation with glucose metabolism, and possibly other health outcomes (1-4, 29).    
Evidence from in vivo and in vitro studies suggests that Se could enhance insulin 
sensitivity by mediating insulin-like actions (30). However, results from human studies on Se 
and glucose metabolism or diabetes risk are conflicting.  Findings from observational studies and 
randomised clinical trials from the US, a Se-replete population, indicate that high Se status or Se 
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supplementation may be associated with an increased risk of type 2 diabetes (5, 10-11).  
Specifically, in a post-hoc analysis of the Nutritional Prevention of Cancer (NPC) trial, in the 
eastern US, we found that supplementation with Se (200 µg/day as high-Se yeast), compared to 
placebo, increased the risk of type 2 diabetes (5), particularly among participants with high 
baseline plasma Se (hazard ratio of 2.70 in the highest tertile of plasma Se, i.e. >121.6 µg/l). 
Moreover, results from the large Se and Vitamin E Cancer Prevention Trial (SELECT) in 35,533 
North American men aged ≥ 50 y (15), showed a small, though non-significant, increase in the 
number of cases of adult-onset diabetes in subjects supplemented with Se alone (200 µg/day as 
selenomethionine).  However, after a further 33 months of follow-up in the SELECT trial, the 
risk of diabetes had diminished: RR 1.04; 99% CI 0.91 to 1.18 (16).  
The overall trial evidence on the effect of Se supplementation on diabetes risk was pooled 
together by our group in a Cochrane review (29). We found a small increased risk of type-2 
diabetes with Se supplementation, which did not reach statistical significance (RR 1.06, 95% CI 
0.97 to 1.15). However, that review included only the limited number of randomized clinical 
trials that administered Se alone, all carried out in US populations (29). 
In European populations, where Se status is generally lower than in the US, the evidence 
linking Se to glucose metabolism is conflicting.  For example, in an early analysis of the EVA 
(Epidemiology of Vascular Ageing) study in France, plasma Se concentrations were positively, 
though non-significantly, associated with baseline glucose levels in women and with prevalent 
diabetes in men (12). However, a later report from the same study showed that high plasma Se 
(1.19-1.97 µmol/L) was associated with a marginally significant reduced risk of hyperglycaemia 
(impaired fasting glucose or diabetes) in men over the 9-year follow-up (31).  Conversely, in a 
prospective study on a large sample of women from Northern Italy, an increased risk of type-2 
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diabetes was associated with higher dietary Se intake; however it has to be admitted that dietary 
assessments of Se intake are unreliable so not much weight can be attached to this result (13). 
With regard to trial evidence, in the French SU.VI.MAX study, no effect of combined 
supplementation with antioxidants including Se (100 µg/day as high-Se yeast), was observed on 
fasting plasma glucose after 7.5 y of follow-up despite a positive association between glucose 
and Se concentrations at baseline in the whole population (32).  More recently, in the UK 
PRECISE Trial among 501 elderly volunteers treated for 6 months with 100, 200 or 300 µg Se/d 
as high-Se yeast or placebo yeast, we found no effect of Se supplementation on plasma 
adiponectin, a surrogate marker of type-2 diabetes risk (24). 
Findings from the Denmark PRECISE trial seem to suggest that Se supplementation is 
unlikely to impair glucose metabolism and increase diabetes risk in populations of relatively low 
Se status. Moreover, small beneficial changes in HbA1c were observed in the treatment groups 
after 6 months of intervention, particularly at the lowest dose level of Se supplementation (100 
µg/d), which is in line with a possible U-shaped relationship between selenium and glucose 
metabolism (1-4, 29). 
In general, the degree to which populations are adequately supplied with a nutrient is 
more variable for Se than for many nutrients. Because of wide differences in geology, soil and 
climatic factors, foods and fodder from different parts of the world vary greatly in their ability to 
provide Se for dietary intake (4). Thus intake ranges from deficient to excessive in China, is 
generally low in Europe, adequate in North America and Japan and is high in Venezuela (4). Se 
status – often measured as serum, plasma, or toenail Se – varies accordingly, reflecting the 
difference in intake in these locations (4). Therefore, the geographic variations in Se intake and 
status across countries and populations are likely to represent one plausible explanation for the 
discrepant results in the published literature.  
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In terms of potential mechanisms to justify a role of Se in glucose metabolism, in vivo 
and in vitro studies have shown anti-diabetic and insulin mimetic effects of Se (generally as 
selenate) (30); however, doses have been used that would be toxic to humans calling into 
question the relevance of these findings (7, 33).  
Type-2 diabetes is associated with oxidative stress attributable to the production of excess 
levels of reactive oxygen species in hyperglycemia (34). As pancreatic β cells are poorly 
protected by intrinsic enzymatic antioxidants and are very susceptible to oxidative injury, it 
might be thought that the antioxidant selenoenzyme, GPx, could protect against that stress (34). 
Indeed overexpression of GPx in islets provided enhanced protection against oxidative stress 
(34), while Se, as selenite or selenate at physiological levels, was able to stimulate pancreatic β-
cell gene expression and enhance islet function (35). Whether as cause or consequence, plasma 
GPx3 concentration was found to be decreased in newly diagnosed, drug-naïve diabetic patients 
compared to subjects with normal or impaired glucose tolerance and was lower in db/db than in 
normal mice (36). Another selenoprotein, SELENOP, appears to protect the β cell against 
endoplasmic reticulum (ER) stress and oxidative stress and may protect against β-cell apoptosis 
(37).  Binding of insulin to its receptor initiates the insulin-signalling cascade, which is 
accompanied by a burst of hydrogen peroxide that acts as a second messenger (7). High activity 
of (cytosolic) GPx1 can interfere with insulin signalling by removing hydrogen peroxide (38). 
Thus, transgenic mice overexpressing GPx1 developed insulin resistance, hyperglycaemia, 
hyperinsulinaemia and obesity (38-39), while knockout of GPx1 improved insulin-induced 
glucose uptake and insulin resistance (40). 
SELENOP has also been implicated in insulin resistance (6). In vitro, in the presence of 
insulin, SELENOP modulated insulin signalling to upregulate mRNA expression of 
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gluconeogenic enzymes, resulting in 30% increase in glucose release. Treatment of mice with 
purified SELENOP impaired insulin signalling in liver and skeletal muscle and induced glucose 
intolerance (6). Conversely, knockdown of the gene for SELENOP in liver improved glucose 
tolerance and reduced insulin resistance in mice with type-2 diabetes while mice deficient in 
SELENOP showed improved glucose tolerance and enhanced insulin signalling (6). It is thought 
that the effect of SELENOP is at least partly through the inactivation of AMP-activated protein 
kinase, a positive regulator of insulin synthesis and secretion in pancreatic β-cells (6).  
Our study has limitations: changes in HbA1c were not the primary endpoint of the 
Denmark PRECISE Trial, hence the need for cautious interpretation of our findings, as they 
result from post-hoc analyses; it was conducted in apparently healthy elderly, so the results may 
not extend to other age groups or participants with different co-morbidities; 71 participants 
dropped out before completing the 2-year intervention period, though they were equally 
distributed between treatment groups and captured in the intention-to-treat mortality analysis. 
Follow-up was only for six months and 2 years, which may not have been long enough to see an 
effect. Importantly, the role of chance in our findings cannot be ruled out as the sample size was 
small and the study was not designed to assess the effect of Se supplementation on HbA1c. 
In conclusion, our findings add to the limited trial evidence on the effect of Se, as a single 
agent at different dose levels, on diabetes risk, in a non-Se-replete population, as most of the 
previous evidence was based on randomized clinical trials conducted among US populations (5, 
15-16, 29).  Overall, our results are reassuring as they do not support potential harmful effects of 
Se supplements on glucose metabolism in populations of relatively low Se status. Further 
research is needed to identify the optimal range of Se intake and status in order to minimize 
potential adverse effects on glucose metabolism while optimising type-2 diabetes prevention (4). 
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Table 1. Baseline characteristics of trial participants overall and by treatment group* 
   Selenium dose (µg/d)  
Characteristic Overall Placebo 100 200 300 P value† 
No. of participants 491 126 124 122 119  
Age (years) 66.1 (4.1) 65.4 (3.8) 66.4 (4.2) 66.3 (4.4) 66.5 (4.1) 0.13 
Sex      0.49 
Men 255 (51.9) 60 (47.6) 70 (56.5) 66 (54.1) 59 (49.6)  
Women 236 (48.1) 66 (52.4) 54 (43.5) 56 (45.9) 60 (50.4)  
Smoking status      0.49 
Never 160 (32.6) 35 (27.8) 42 (33.9) 40 (32.8) 43 (36.2)  
Former 185 (37.7) 48 (38.1) 47 (37.9) 52 (42.6) 38 (31.9)  
Current 146 (29.7) 43 (34.1) 35 (28.2) 30 (24.6) 38 (31.9)  
Alcohol drinking (drinks/week)      0.76 
≤ 2 170 (34.6) 47 (37.3) 41 (33.1) 40 (32.8) 42 (35.3)  
3–10 209 (42.6) 48 (38.1) 51 (41.1) 55 (45.1) 55 (46.2)  
> 10 112 (22.8) 31 (24.6) 32 (25.8) 27 (22.1) 22 (18.5)  
Body mass index (kg/m
2
) 26.8 (4.1) 26.5 (4.0) 27.1 (4.0) 27.2 (4.3) 26.5 (4.0) 0.40 
Plasma selenium      0.17 
ng/g 86.5 (16.3) 86.0 (15.2) 87.5 (16.4) 88.3 (16.2) 83.9 (17.1)  
µg/L 88.6 (16.7) 88.2 (15.6) 89.7 (16.8) 90.5 (16.6) 86.0 (17.5)  
HbA1c      0.34 
mmol/mol 36.6 (7.0) 35.7 (5.7) 37.4 (7.4) 36.6 (7.9) 36.7 (7.0)  
% 5.5 (0.6) 5.4 (0.5) 5.6 (0.7) 5.5 (0.7) 5.5 (0.6)  
Use of diabetes medication 6 (1.2) 1 (0.8) 3 (2.4) 1 (0.8) 1 (0.8) 0.70 
* Data are means (SDs) or numbers (%). 
† P value for homogeneity of means or proportions across the four treatment groups. 
HbA1c, glycated hemoglobin. 
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Table 2. Effect of selenium supplementation on changes in HbA1c and plasma selenium concentrations after 6 months and 2 years* 
  Selenium dose (µg/d)  
Variable Placebo 100 200 300 P value† 
HbA1c (mmol/mol)      
Mean (SD) at baseline 35.7 (5.7) 37.4 (7.4) 36.6 (7.9) 36.7 (7.0)  
Mean (SD) at 6 mo 36.4 (5.2) 37.1 (8.3) 36.9 (7.3) 36.5 (4.8)  
Change from baseline to 6 mo (95% CI) 0.7 (-0.2 to 1.6) -0.8 (-1.7 to 0.1) 0.1 (-0.9 to 1.0) 0.0 (-0.9 to 0.9)  
Difference in change (95% CI) 0 (Reference) -1.5 (-2.8 to -0.2) -0.7 (-2.0 to 0.6) -0.7 (-2.0 to 0.6) 0.16 
P value  0.02 0.32 0.30  
Mean (SD) at 2 yr 34.0 (7.2) 34.8 (7.2) 34.9 (7.7) 33.8 (7.8)  
Change from baseline to 2 yr (95% CI) -1.8 (-3.1 to -0.6) -2.7 (-4.0 to -1.4) -1.7 (-3.0 to -0.3) -2.8 (-4.1 to -1.5)  
Difference in change (95% CI) 0 (Reference) -0.9 (-2.7 to 0.9) 0.1 (-1.7 to 2.0) -1.0 (-2.8 to 0.8) 0.52 
P value  0.35 0.88 0.30  
Plasma selenium‡ (ng/g)      
Mean (SD) at baseline 86.0 (15.2) 87.5 (16.4) 88.3 (16.2) 83.9 (17.1)  
Mean (SD) at 6 mo 85.3 (14.2) 152.4 (23.7) 209.1 (41.5) 253.7 (54.1)  
Change from baseline to 6 mo (95% CI) -0.8 (-8.0 to 6.4) 64.8 (57.7 to 71.9) 120.9 (113.7 to 128.0) 169.8 (162.4 to 177.1)  
Difference in change (95% CI) 0 (Reference) 65.6 (55.6 to 75.7) 121.7 (111.6 to 131.9) 170.6 (160.3 to 180.9) < 0.001 
P value  < 0.001 < 0.001 < 0.001  
* Results were obtained from linear mixed models with fixed treatment-by-time interactions and random between-subject variations in both baseline HbA1c levels and HbA1c 
changes over time. 
† Overall P value comparing the three active treatment groups with placebo. 
‡ Plasma selenium measurements were not available at 2 years of follow-up. 
HbA1c, glycated hemoglobin. 
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Table 3. Cross-sectional association between plasma selenium and HbA1c levels at baseline* 
  Quartile of baseline selenium (ng/g)  
 
Variable 
50-ng/g increase in 
baseline selenium 
First 
(43 to 76) 
Second 
(77 to 85) 
Third 
(86 to 95) 
Fourth 
(96 to 159) 
P value 
for trend† 
Median baseline selenium (ng/g) 85 70 80 89 104  
No. of participants 488 126 129 114 119  
HbA1c (mmol/mol)       
Mean (SD) at baseline 36.6 (7.0) 37.4 (8.0) 36.5 (6.7) 36.0 (5.5) 36.6 (7.6)  
Adjusted mean difference -1.1 0 -0.3 -1.2 -0.8 0.18 
(95% CI) (-2.6 to 0.5) (Reference) (-1.7 to 1.1) (-2.7 to 0.2) (-2.3 to 0.6)  
* Results were obtained from linear mixed models with random between-subject variations in baseline HbA1c levels and adjusted for baseline age (continuous), sex, smoking status 
(never, former, or current), alcohol drinking (≤ 2, 3–10, or > 10 drinks/week), body mass index (continuous), and use of diabetes medications. 
† P value for linear trend using an ordinal variable with the median baseline selenium level in each quartile. 
HbA1c, glycated hemoglobin. 
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Table 4. Longitudinal association between changes in plasma selenium and HbA1c levels after 6 months* 
  Quartile of selenium change (ng/g)  
 
Variable 
50-ng/g increase in 
selenium over time 
First 
(-48 to 24) 
Second 
(25 to 81) 
Third 
(82 to 138) 
Fourth 
(139 to 355) 
 
P value† 
Median selenium change (ng/g) 81 -2 58 107 172  
No. of participants 432 108 108 110 106  
HbA1c (mmol/mol)       
Mean (SD) change at 6 mo -0.1 (4.8) 0.5 (4.1) -1.2 (4.6) -0.5 (6.2) 0.9 (3.8)  
Adjusted difference in change 0.1 0 -1.5 -0.4 0.3 0.02 
(95% CI) (-0.1 to 0.4) (Reference) (-2.6 to -0.3) (-1.5 to 0.8) (-0.8 to 1.5)  
* Results were obtained from linear mixed models with random between-subject variations in both baseline HbA1c levels and HbA1c changes over time and adjusted for baseline 
selenium concentration (continuous), age (continuous), sex, smoking status (never, former, or current), alcohol drinking (≤ 2, 3–10, or > 10 drinks/week), body mass index 
(continuous), and use of diabetes medications. 
† Overall P value comparing the three highest quartiles of selenium change with the lowest quartile. 
HbA1c, glycated hemoglobin. 
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FIGURE LEGENDS 
Figure 1. Study flow diagram. 
HbA1c, glycated hemoglobin. 
Figure 2. Differences in mean HbA1c changes after 6 months comparing the three active 
treatment groups with placebo by pre-specified baseline subgroup. 
Subgroup-specific differences in mean HbA1c changes (squares with area inversely proportional to the variance) and 
their 95% CIs (horizontal lines) were obtained from linear mixed models with fixed interactions between treatment 
group, time, and the corresponding baseline covariate and random between-subject variations in both baseline HbA1c 
levels and HbA1c changes over time. HbA1c, glycated hemoglobin; Se, selenium. 
Figure 3. Changes in HbA1c levels after 6 months by change in plasma selenium concentration. 
Curve represents mean changes in HbA1c levels from baseline to 6 months (solid line) and their 95% CIs (shaded 
region) based on restricted quadratic splines for changes in plasma selenium concentrations with knots at the 5th, 
50th, and 95th percentiles (-11, 81, and 217 ng/g, respectively). Results were obtained from a linear mixed model 
with random between-subject variations in both baseline HbA1c levels and HbA1c changes over time and adjusted for 
baseline selenium levels (continuous), age (continuous), sex, smoking status (never, former, or current), alcohol 
drinking (≤ 2, 3–10, or > 10 drinks/week), body mass index (continuous), and use of diabetes medications. 
Scatterplot represents changes in plasma selenium and HbA1c levels after 6 months for participants randomized to 
placebo (green dots), 100 µg/d (blue dots), 200 µg/d (orange dots), and 300 µg/d (red dots) of selenium 
supplementation. HbA1c, glycated hemoglobin. 
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Assessed for eligibility (n = 2,897)
Randomized (n = 491)
Excluded (n = 2,406)
Declined to participate: 2,267
Did not meet inclusion criteria: 63
Did not complete placebo run-in: 5
Withdrew consent: 38
Unknown/personal reasons: 33
Allocated to placebo (n = 126)
Received allocation: 126
Allocated to 300 µg/d (n = 119)
Received allocation: 119
Allocated to 200 µg/d (n = 122)
Received allocation: 122
Allocated to 100 µg/d (n = 124)
Received allocation: 124
Baseline HbA1c measurement 
available (n = 123)
Missing blood sample: 1
Baseline HbA1c measurement
available (n = 126)
Baseline HbA1c measurement
available (n = 121)
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available (n = 119)
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(n = 2)
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Deaths: 1
Adverse events: 3
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Withdrew consent: 1
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available (n = 113)
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available (n = 104)
Missing blood sample: 9
Drop-outs between 6 mo
and 2 yr (n = 7)
Deaths: 1
Adverse reactions: 1
Withdrew consent: 3
Unknown/personal
reasons: 2
Drop-outs between 6 mo
and 2 yr (n = 16)
Deaths: 2
Adverse events: 5
Adverse reactions: 4
Withdrew consent: 5
Drop-outs between 6 mo
and 2 yr (n = 18)
Deaths: 1
Adverse events: 7
Adverse reactions: 5
Withdrew consent: 2
Unknown/personal
reasons: 3
Drop-outs between 6 mo
and 2 yr (n = 7)
Deaths: 3
Adverse events: 1
Adverse reactions: 1
Withdrew consent: 1
Unknown/personal
reasons: 1
2-yr HbA1c measurement
available (n = 99)
Missing blood sample: 10
2-yr HbA1c measurement 
available (n = 90)
Missing blood sample: 16
2-yr HbA1c measurement
available (n = 86)
Missing blood sample: 13
2-yr HbA1c measurement
available (n = 94)
Missing blood sample: 12
Analyzed: HbA1c measures 
available at baseline, 6 mo, or 
2 yr (n = 126)
Analyzed: HbA1c measures 
available at baseline, 6 mo,
or 2 yr (n = 124)
Analyzed: HbA1c measures 
available at baseline, 6 mo,
or 2 yr (n = 122)
Analyzed: HbA1c measures 
available at baseline, 6 mo,
or 2 yr (n = 119)
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STATISTICAL APPENDIX 
For the analysis of randomized groups, the linear mixed model for HbA1c levels Yij at baseline j = 0, 
6-month j = 1, and 2-year visits j = 2 for participant i was 
 Yij = (β00 + bi0) + β01Ti1 + β02Ti2 + β03Ti3 
  + (β10 + bi1)t1 + β11Ti1t1 + β12Ti2t1 + β13Ti3t1 
  + (β20 + bi2)t2 + β21Ti1t2 + β22Ti2t2 + β23Ti3t2 + εij, 
where Ti1, Ti2, and Ti3 were treatment indicators for the three active treatment groups of 100, 200, 
and 300 µg/d of selenium supplementation, respectively; t1 and t2 were time indicators for 6-month 
and 2-year follow-up visits, respectively; and the within-subject error εij and the between-subject 
variations bi0, bi1, and bi2 were assumed to be independent and normally distributed with mean 0 
and constant variances. In this model, the fixed effect β00 represented the mean baseline HbA1c level 
for the placebo group; the fixed effects β01, β02, and β03 represented the differences in mean baseline 
HbA1c levels for the three active treatment groups compared with placebo; and the random effect bi0 
represented the unexplained between-subject variation in baseline HbA1c levels. Also, the fixed 
effect β10 represented the mean HbA1c change from baseline to 6 months for the placebo group; the 
fixed effects β11, β12, and β13 represented the differences in mean HbA1c changes from baseline to 6 
months for the three active treatment groups compared with placebo (treatment effect at 6 months); 
and the random effect bi1 represented the unexplained between-subject variation in HbA1c changes 
from baseline to 6 months. Similarly, the fixed effect β20 represented the mean HbA1c change from 
baseline to 2 years for the placebo group; the fixed effects β21, β22, and β23 represented the 
differences in mean HbA1c changes from baseline to 2 years for the three active treatment groups 
compared with placebo (treatment effect at 2 years); and the random effect bi2 represented the 
unexplained between-subject variation in HbA1c changes from baseline to 2 years. 
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To assess the cross-sectional and longitudinal associations between plasma selenium and 
HbA1c concentrations, the linear mixed model for HbA1c levels Yij at baseline j = 0 and 6 months j = 
1 for participant i was 
 Yij = (β00 + bi0) + β01xi0 + β′02zi0 
  + (β10 + bi1)t1 + β11(xij – xi0) + εij, 
where xij was the plasma selenium level at visit j and zi0 were other covariates measured at baseline, 
including age, sex, smoking status, alcohol drinking, body mass index, and use of diabetes 
medications. The fixed effect β00 represented the mean baseline HbA1c level at 0 values of selenium 
and other baseline covariates; the fixed effect β01 represented the covariate-adjusted mean 
difference in baseline HbA1c levels per unit increase in baseline selenium levels (cross-sectional 
association at baseline); the fixed effects β02 represented the adjusted coefficients for the other 
baseline covariates; and the random effect bi0 was the unexplained between-subject variation in 
baseline HbA1c levels. In addition, the fixed effect β10 represented the mean HbA1c change from 
baseline to 6 months when selenium remained unchanged; the fixed effect β11 represented the 
difference in mean HbA1c changes from baseline to 6 months per unit change in selenium levels 
adjusted for baseline covariates (longitudinal association at 6 months); and the random effect bi1 
was the unexplained between-subject variation in HbA1c changes over time. 
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